Osso VR: The company raised $66 million of Series C venture funding in a deal led by Oak HC/FT on March 24, 2022, putting the company’s pre-money valuation at $158 million. Kaiser Permanente Ventures, Tiger Global Management, SignalFire, GSR Ventures, and other undisclosed investors also participated in the round. The company is a developer of a virtual reality platform designed to focus on surgical and medical device training.
nirvanaHealth: The company raised $60 million of venture funding from undisclosed investors on March 22, 2022. The company is a developer of a robotic process automation cloud platform designed to perform core business functions and drive automation.
Replicate Bioscience: The company is in process of raising $53 million of venture funding on March 25, 2022. The company is an operator of a biopharmaceutical company intended to create novel treatments for cancer.
TimeDoc Health: The company raised $48.5 million of Series B venture funding in a deal led by Aldrich Capital Partners on March 21, 2022. The company is a developer of a chronic care management platform designed to manage, provide, and coordinate care management services.
List Biotherapeutics: The company raised $48.4 million of Series A venture funding from Hana Ventures, DSC Investment, and Paratus Investment on March 23, 2022, putting the pre-money valuation at $78 million. SV Investment and an undisclosed investor also participated in the round. The company is an operator of a biotech business intended to develop microbiome drugs.
Podimetrics: The company raised $45 million through a combination of debt and Series C venture funding in a deal led by D1 Capital Partners on March 24, 2022, putting the company’s pre-money valuation at $170 million. Scientific Health Development, Polaris Partners, SV Health Investors, and other undisclosed investors also participated in the round. The company is a provider of care management services and technologies intended to prevent diabetic foot complications.
Huma: The company raised an estimated $33 million from AstraZeneca on March 23, 2022. The company is a developer of a mobile application designed to improve digital health through data.
Nucleai: The company raised $33 million of Series B venture funding in a deal led by Sanofi Ventures and Section 32 on March 22, 2022. Debiopharm Innovation Fund, Fosun RZ Capital, Vertex Ventures Israel, and Grove Ventures also participated in the round. The company is a developer of an artificial intelligence-based cancer diagnosis platform designed to transform biomarker discovery and treatment decisions.
BRAINBox Solutions: The company raised $28 million of Series A venture funding in a deal led by BioVentures Investors on March 22, 2022, putting the company’s pre-money valuation at $10 million. Astia, VTC Ventures, Genoa Ventures, Blue Leaf Ventures, Ambit Health Ventures, Kevin Love, and the Laszlo N. Tauber Family Foundation also participated in the round. The company is a developer of a medical technology platform designed to offer a multi-modality approach for the diagnosis and prognosis of mild traumatic brain injuries.
Antidote: The company raised $22 million of Series A venture funding in a deal led by Flint Capital, iAngels, and Group 11 on March 22, 2022. The company is an operator of a telemedicine application designed to provide affordable premium healthcare.
BioAegis Therapeutics: The company raised $22 million of venture funding in a deal led by European Investment Fund on March 22, 2022. Other undisclosed investors also participated in the round. The company is an operator of a clinical-stage drug development platform intended to facilitate the treatment of inflammation and infectious diseases.
PreludeDx: The company raised $20 million of venture funding in a deal led by Evidity Health Capital on March 22, 2022. BlueStone Venture Partners and other undisclosed investors also participated in this round. The company is a developer of decision-making tools intended to manage early-stage breast cancer.
Sterifre Medical: The company is in the process of raising $20 million of Series C venture funding from undisclosed investors on March 24, 2022. The company is a developer of a plug-and-play healthcare technology designed to eliminate disinfection and sterilization in the healthcare environment.
Vivante Health: The company raised $18.2 million of Series A venture funding in a deal led by 7wire Ventures on March 24, 2022. NFP Ventures, Intermountain Ventures, Leaps by Bayer, FCA Venture Partners, SemperVirens Venture Capital, Elements Health Ventures, Lifeforce Capital, Big Pi Ventures, and Human Capital also participated in the round. The company is a developer of a chronic disease management platform and programs designed to manage gut health and combat associated diseases.
Linus Biotechnology: The company raised $17.5 million of venture funding from Divergent Investments and other undisclosed investors on March 21, 2022. The company is an operator of a patient-centric medicine company intended to improve human health through precision exposome medicine.
geneos Therapeutics: The company raised $17 million of Series A2 venture funding in a deal led by Flerie Invest on March 24, 2022. Inovio Pharmaceuticals, Santé, Korea Investment Partners, and Global BIO Impact Fund also participated in the round. The company is a developer of a neo-antigen-based personalized immunotherapy designed to offer cancer treatment.
Spine BioPharma: The company raised $13 million of venture funding from undisclosed investors on March 23, 2022. The company is a provider of non-surgical therapies intended to reduce pain, restore function, and slow or stop pathological spinal disease progression without the use of opioids.
Qu Biologics: The company raised $12 million of venture funding from undisclosed investors on March 21, 2022. The company is a developer of a site-specific immunotherapy designed to restore the body’s normal immune function to treat cancer and other immune-related diseases.
TestCard: The company raised GBP 5.5 million of venture funding from East Post Road Ventures and other undisclosed investors on March 21, 2022, putting the company’s pre-money valuation at GBP 35.1 million. The company is a developer of a medical diagnostic technology designed to provide non-invasive at-home testing.
Kyra Medical: The company raised $5.8 million of venture funding from undisclosed investors on March 24, 2022. The company is a developer of medical devices intended for gynecology, laparoscopy, and urology procedures.
Post Acute Analytics: The company raised $3 million of venture funding from undisclosed investors on March 24, 2022. The company is a developer of an advanced predictive technology designed to positively impact the total quality and cost of care.
